In contrast Sarah B Fisher et al. analyzed the HER2 status of 111 patients with G/GEJ adenocarcinoma and suggested that HER2 overexpression/amplification was not associated with poor prognosis [20]. Here, ERBB2 is linked to adenocarcinoma.